treatment approaches for asct-eligible myeloma patients in the frontline
Published 3 years ago • 38 plays • Length 3:01Download video MP4
Download video MP3
Similar videos
-
1:30
is asct the right answer for all transplant eligible mm patients?
-
1:23
managing patients with multiple myeloma who have stopped treatment prior to relapse
-
0:55
the significance of cr as an endpoint in frail patients with multiple myeloma
-
4:46
does asct still have a place in myeloma treatment?
-
0:48
the role of transplant in myeloma
-
3:02
myeloma uk autologous stem cell transplantation
-
41:03
multiple myeloma: a patient’s perspective | dana-farber cancer institute
-
2:29
the safety and feasibility of car-t & bispecifics in patients with myeloma after prior allosct
-
2:23
management of newly diagnosed patients with multiple myeloma not eligible for transplantation
-
2:50
current standard of care for patients who are eligible for autologous stem cell transplantation
-
1:09
using mrd and pet/ct to assess responses post-asct in myeloma
-
1:52
upfront asct for newly diagnosed multiple myeloma: double vs. single transplant
-
1:48
the role of autologous transplantation in young and fit patients with multiple myeloma in 2022
-
1:04
the changing role of autosct in the treatment of multiple myeloma in the era of novel agents
-
2:49
the importance of timing in autologous transplantation for multiple myeloma
-
1:33
the role of allogeneic transplantation in patients with multiple myeloma
-
5:52
transplant for all eligible mm patients?
-
3:34
management of transplant-eligible myeloma patients in 2017
-
1:36
the relevance of sct in multiple myeloma
-
2:30
a new era of treatment for multiple myeloma
-
1:30
risk assessment & transplant decisions in multiple myeloma
-
2:39
a look into the future of multiple myeloma treatment: t-cell redirecting therapies vs autohsct